Enhancing diagnostic accuracy of aMCI in the elderly: Combination of olfactory test, pupillary response test, BDNF plasma level, and APOE genotype

International Journal of Alzheimer's Disease

Volumn 2014, Issue , 2014, Pages

  Turana, Yuda ^a   Ranakusuma, Teguh Asaat S ^b   Purba, Jan Sudir ^b   Amir, Nurmiati ^b   Ahmad, Siti Airiza ^b   Machfoed, Moh Hasan ^c   Handayani, Yvonne Suzy ^a   Asmarinah, ^b   Waspadji, Sarwono ^b  

^a ATMA JAYA CATHOLIC UNIVERSITY OF INDONESIA   (Indonesia)

^b UNIVERSITY OF INDONESIA   (Indonesia)

^c AIRLANGGA UNIVERSITY   (Indonesia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; BRAIN DERIVED NEUROTROPHIC FACTOR; TROPICAMIDE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DRUG HYPERSENSITIVITY; FEMALE; GENOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; MYDRIASIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PUPILLARY RESPONSE TEST; RECEIVER OPERATING CHARACTERISTIC; SMELL TEST;

EID: 84896853524     PISSN: None     EISSN: 20900252     Source Type: Journal    
DOI: 10.1155/2014/912586     Document Type: Article

References (72)

1. Petersen R. C., Smith G. E., Waring S. C., Ivnik R. J., Tangalos E. G., Kokmen E., Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology 1999 56 3 303 308 2-s2.0-0032988610
2. Schmidtke K., Hermeneit S., High rate of conversion to Alzheimer's disease in a cohort of amnestic MCI patients. International Psychogeriatrics 2008 20 1 96 108 2-s2.0-37149008054 10.1017/S1041610207005509
3. Petersen R. C., Parisi J. E., Dickson D. W., Johnson K. A., Knopman D. S., Boeve B. F., Jicha G. A., Ivnik R. J., Smith G. E., Tangalos E. G., Braak H., Kokmen E., Neuropathologic features of amnestic mild cognitive impairment. Archives of Neurology 2006 63 5 665 672 2-s2.0-33646392455 10.1016/j. archoralbio.2006.02.003
4. McCaffrey R. J., Duff K., Solomon G. S., Olfactory dysfunction discriminates probable Alzheimer's dementia from major depression: a cross-validation and extension. Journal of Neuropsychiatry and Clinical Neurosciences 2000 12 1 29 33 2-s2.0-0033953435
5. Serby M., Larson P., Kalkstein D., The nature and course of olfactory deficits in Alzheimer's disease. The American Journal of Psychiatry 1991 148 3 357 360 2-s2.0-0026019518
6. Doty R. L., Marcus A., Lee W. W., Development of the 12 item cross cultural smell identification test (CC-SIT). Laryngoscope 1996 106 3 353 356 2-s2.0-0029976127
7. Eibenstein A., Fioretti A. B., Simaskou M. N., Sucapane P., Mearelli S., Mina C., Amabile G., Fusetti M., Olfactory screening test in mild cognitive impairment. Neurological Sciences 2005 26 3 156 160 2-s2.0-23944478165 10.1007/s10072-005-0453-2
8. Tabert M. H., Liu X., Doty R. L., Serby M., Zamora D., Pelton G. H., Marder K., Albers M. W., Stern Y., Devanand D. P., A 10-item smell identification scale related to risk for Alzheimer's disease. Annals of Neurology 2005 58 1 155 160 2-s2.0-21844469971 10.1002/ana.20533
9. Wang Q.-S., Tian L., Huang Y.-L., Qin S., He L.-Q., Zhou J.-N., Olfactory identification and apolipoprotein E ε 4 allele in mild cognitive impairment. Brain Research 2002 951 1 77 81 2-s2.0-0037183729 10.1016/S0006-8993(02)03137-2
10. Graves A. B., Bowen J. D., Rajaram L., McCormick W. C., McCurry S. M., Schellenberg G. D., Larson E. B., Impaired olfaction as a marker for cognitive decline: interaction with apolipoprotein E ε 4. Neurology 1999 53 7 1480 1487 2-s2.0-0000954482
11. Devanand D. P., Michaels-Marston K. S., Liu X., Pelton G. H., Padilla M., Marder K., Bell K., Stern Y., Mayeux R., Olfactory deficits in patients with mild cognitive impairment predict Alzheimer's disease at follow-up. The American Journal of Psychiatry 2000 157 9 1399 1405 2-s2.0-0033856181 10.1176/appi.ajp.157.9.1399
12. Murphy C., Jernigan T. L., Fennema-Notestine C., Left hippocampal volume loss in Alzheimer's disease is reflected in performance on odor identification: a structural MRI study. Journal of the International Neuropsychological Society 2003 9 3 459 471 2-s2.0-0037350235 10.1017/S1355617703930116
13. Warner M. D., Peabody C. A., Flattery J. J., Tinklenberg J. R., Olfactory deficits and Alzheimer's disease. Biological Psychiatry 1986 21 1 116 118 2-s2.0-0022483283
14. Koss E., Olfactory dysfunction in Alzheimer's disease. Developmental Neuropsychology 1986 2 2 89 99
15. Doty R. L., Reyes P. F., Gregor T., Presence of both odor identification and detection deficits in Alzheimer's disease. Brain Research Bulletin 1987 18 5 597 600 2-s2.0-0023201973
16. Koss E., Weiffenbach J. M., Haxby J. V., Friedland R. P., Olfactory detection and identification performance are dissociated in early Alzheimer's disease. Neurology 1988 38 8 1228 1232 2-s2.0-0023686607
17. Scinto L. F. M., Daffner K. R., Dressler D., Ransil B. I., Rentz D., Weintraub S., Mesulam M., Potter H., A potential noninvasive neurobiological test for Alzheimer's disease. Science 1994 266 5187 1051 1054 2-s2.0-0027938026
18. Grünberger J., Linzmayer L., Walter H., Rainer M., Masching A., Pezawas L., Saletu-Zyhlarz G., Stöhr H., Grünberger M., Receptor test (pupillary dilatation after application of 0.01% tropicamide solution) and determination of central nervous activation (Fourier analysis of pupillary oscillations) in patients with Alzheimer's disease. Neuropsychobiology 1999 40 1 40 46 2-s2.0-0345643447 10.1159/000026595
19. Fourie J., Age dependent pupillary and cognitive responses to cholinergic drugs as a model for identification of future biological markers for Alzheimer disease [Ph.D. thesis] 1999 Toronto, Canada University of Toronto
20. Iijima A., Haida M., Ishikawa N., Ueno A., Minamitani H., Shinohara Y., Re-evaluation of tropicamide in the pupillary response test for Alzheimer's disease. Neurobiology of Aging 2003 24 6 789 796 2-s2.0-0142043974 10.1016/S0197-4580(02)00235-X
21. Higuchi S., Matsushita S., Hasegawa Y., Muramatsu T., Arai H., Hayashida M., Apolipoprotein E ε 4 allele and pupillary response to tropicamide. The American Journal of Psychiatry 1997 154 5 694 696 2-s2.0-0030611873
22. Gómez-Tortosa E., del Barrio A., Jiménez-Alfaro I., Pupil response to tropicamide in Alzheimer's disease and other neurodegenerative disorders. Acta Neurologica Scandinavica 1996 94 2 104 109 2-s2.0-0029781240
23. Higuchi S., Matsushita S., Hasegawa Y., Muramatsu T., Arai H., Pupillary response to tropicamide in Japanese patients with alcoholic dementia, Alzheimer's disease, and vascular dementia. Experimental Neurology 1997 144 1 199 201 2-s2.0-0031105523 10.1006/exnr.1997.6417
24. Imamura Y., Kojima H., Haraoka K., Pupil dilatation response to the acethylcholine receptor antagonist tropicamide in normal aged and senile dementia subjects. Neurobiology of Aging 1996 17 4, supplement 1 S165
25. Kálmán J., Kanka A., Maglóczky E., Szóke A., Járdánházy T., Janka Z., Increased mydriatic response to tropicamide is a sign of cholinergic hypersensitivity but not specific to late-onset sporadic type of Alzheimer's dementia. Biological Psychiatry 1997 41 8 909 911 2-s2.0-0343990727 10.1016/S0006-3223(97)00021-8
26. Matsushita S., Arai H., Hasegawa Y., Apolipoprotein Ee4 allele and pupillary response to tropicamide in Alzheimer's disease and cognitively normal subjects. Neurobiology of Aging 1996 17 4, supplement 1 S164
27. Titus A. M., Revest P., Shortland P., The Nervous System, Basic Science and Clinical Conditions 2007 New York, NY, USA Elseiver
28. Ertekin-Taner N., Genetics of Alzheimer's disease: a centennial review. Neurologic Clinics 2007 25 3 611 667 2-s2.0-34447316702 10.1016/j.ncl.2007.03. 009
29. Polvikoski T., Sulkava R., Haltia M., Kainulainen K., Vuorio A., Verkkoniemi A., Niinisto L., Halonen P., Kontula K., Apolipoprotein E, dementia, and cortical deposition of β -amyloid protein. The New England Journal of Medicine 1995 333 19 1242 1247 2-s2.0-0028841027 10.1056/NEJM199511093331902
30. Petersen R. C., Smith G. E., Ivnik R. J., Tangalos E. G., Schaid D. J., Thibodeau S. N., Kokmen E., Waring S. C., Kurland L. T., The APOE ε 4 status as a predictor of the developmental of Alzheimer's disease in memory impaired individuals. The Journal of the American Medical Association 1995 273 16 1274 1278 2-s2.0-0028898784
31. Small B. J., Rosnick C. B., Fratiglioni L., Bäckman L., APOE ε 4 and cognitive performance: a metaanalysis. Psychology and Aging 2004 19 4 592 600 2-s2.0-10044243556 10.1037/0882-7974.19.4.592
32. van der Vlies A. E., Pijnenburg Y. A. L., Koene T., Klein M., Kok A., Scheltens P., Van Der Flier W. M., Cognitive impairment in Alzheimer's disease is modified by APOE genotype. Dementia and Geriatric Cognitive Disorders 2007 24 2 98 103 2-s2.0-34447636046 10.1159/000104467
33. Ramakers I. H. G. B., Visser P. J., Aalten P., Bekers O., Sleegers K., Van Broeckhoven C. L., Jolles J., Verhey F. R. J., The association between APOE genotype and memory dysfunction in subjects with mild cognitive impairment is related to age and Alzheimer pathology. Dementia and Geriatric Cognitive Disorders 2008 26 2 101 108 2-s2.0-51849108660 10.1159/000144072
34. Boyle P. A., Buchman A. S., Wilson R. S., Kelly J. F., Bennett D. A., The APOE ε 4 allele is associated with incident mild cognitive impairment among community-dwelling older persons. Neuroepidemiology 2010 34 1 43 49 2-s2.0-70449513319 10.1159/000256662
35. Cunha C., Brambilla R., Thomas K. L., A simple role for BDNF in learning and memory? Frontiers in Molecular Neuroscience 2010 3 1 14 2-s2.0-84860118330 10.3389/neuro.02.001.2010
36. Laske C., Stransky E., Leyhe T., Eschweiler G. W., Maetzler W., Wittorf A., Soekadar S., Richartz E., Koehler N., Bartels M., Buchkremer G., Schott K., BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. Journal of Psychiatric Research 2007 41 5 387 394 2-s2.0-33846640660 10.1016/j.jpsychires.2006.01.014
37. Pan W., Banks W. A., Fasold M. B., Blunth J., Katin A. J., Transport of BDNF across the BBB. Neuropharmacology 2006 37 12 1553 1561
38. Dogliotti G., Galliera E., Licastro F., Corsi M. M., Age-related changes in plasma levels of BDNF in Down syndrome patients. Immunity and Ageing 2010 7, article 2 2-s2.0-77649327305 10.1186/1742-4933-7-2
39. Yu H., Zhang Z., Shi Y., Bai F., Xie C., Qian Y., Yuan Y., Deng L., Association study of the decreased serum BDNF concentrations in amnestic mild cognitive impairment and the Val66Met polymorphism in Chinese han. Journal of Clinical Psychiatry 2008 69 7 1104 1111 2-s2.0-47749126147
40. Lee J. G., Shin B. S., You Y. S., Decreased serum brain-derived neurotrophic factor levels in elderly Korean with dementia. Psychiatry Investigation 2009 6 4 299 305 2-s2.0-75649087374 10.4306/pi.2009.6.4.299
41. Hwang K. S., Gylys K., Taylor K., Plasma BDNF associations with cortical thickness in normal controls and mild cognitive impairment. Alzheimer's & Dementia 2011 7 4, supplement S319
42. von Bohlen O., Halbach, Involvement of BDNF in age-dependent alterations in the hippocampus. Frontiers in Aging Neuroscience 2010 2 1 11
43. Suchowersky O., Reich S., Perlmutter J., Zesiewicz T., Gronseth G., Weiner W. J., Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006 66 7 968 975 2-s2.0-33646082990 10.1212/01.wnl.0000215437.80053.d0
44. Handajani Y. S., Disability measurement index and prediction of the life quality of the elderly in DKI Jakarta [Ph.D. thesis] 2006 Depok, Indonesia University of Indonesia
45. Yesavage J. A., Brink T. L., Rose T. L., Development and validation of a geriatric depression screening scale: a preliminary report. Journal of Psychiatric Research 1983 17 1 37 49 2-s2.0-0020286558 10.1016/0022-3956(82) 90033-4
46. American Diabetes Association, Standard of medical care in diabetes 2012. Diabetes Care 2012 35 S11 S63
47. Asian-Pacific Type 2 Diabetes Policy Group, Type 2 Diabetes: Practical Targets and Treatments 2002 3rd Melbourne, Australia
48. Welsh K. A., Butters N., Mohs R. C., Beekly D., Edland S., Fillenbaum G., Heyman A., The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology 1994 44 4 609 614 2-s2.0-0028285127
49. Winblad B., Palmer K., Kivipelto M., Jelic V., Fratiglioni L., Wahlund L.-O., Nordberg A., Bäckman L., Albert M., Almkvist O., Arai H., Basun H., Blennow K., De Leon M., Decarli C., Erkinjuntti T., Giacobini E., Graff C., Hardy J., Jack C., Jorm A., Ritchie K., Van Duijn C., Visser P., Petersen R. C., Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine 2004 256 3 240 246 2-s2.0-4544350756 10.1111/j.1365-2796.2004. 01380.x
50. Luhur J. J., Mirsha, Handajani Y. S., Turana Y., Determination of familiar odors for standard examination of olfactory function of the elderly in Jakarta. Neurona 2012 29 7 13
51. Yoon M. K., Schmidt G., Lietman T., McLeod S. D., Interexaminer and intraexaminer reliability of pupil diameter measurement using the colvard pupillometer. Investigative Ophthalmology and Visual Science 2003 44
52. Bootsma S., Tahzib N., Eggink F., de Brabander J., Nuijts R. M. M. A., Comparison of two pupillometers in determining pupil size for refractive surgery. Acta Ophthalmologica Scandinavica 2007 85 3 324 328 2-s2.0-34248195567 10.1111/j.1600-0420.2006.00823.x
53. Granholm E., Morris S., Galasko D., Shults C., Rogers E., Vukov B., Tropicamide effects on pupil size and pupillary light reflexes in Alzheimer's and Parkinson's disease. International Journal of Psychophysiology 2003 47 2 95 115 2-s2.0-0037306829 10.1016/S0167-8760(02)00122-8
54. Luck T., Riedel-Heller S. G., Kaduszkiewicz H., Bickel H., Jessen F., Pentzek M., Wiese B., Koelsch H., Van Den Bussche H., Abholz H.-H., Moesch E., Gorfer S., Angermeyer M. C., Maier W., Weyerer S., Mild cognitive impairment in general practice: age-specific prevalence and correlate results from the German study on ageing, cognition and dementia in primary care patients (AgeCoDe). Dementia and Geriatric Cognitive Disorders 2007 24 4 307 316 2-s2.0-34748831097 10.1159/000108099
55. Blom E. S., Giedraitis V., Zetterberg H., Fukumoto H., Blennow K., Hyman B. T., Irizarry M. C., Wahlund L.-O., Lannfelt L., Ingelsson M., Rapid progression from mild cognitive impairment to alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the Apoe ε 4/ ε 4 genotype. Dementia and Geriatric Cognitive Disorders 2009 27 5 458 464 2-s2.0-65449157673 10.1159/000216841
56. Arai H., Terajima M., Nakagawa T., Higuchi S., Mochizuki H., Sasaki H., Pupil dilatation assay by tropicamide is modulated by apolipoprotein e 4 allele dosage in Alzheimer's disease. NeuroReport 1996 7 4 918 920 2-s2.0-0029995524
57. Petersen R. C., Stevens J. C., Ganguli M., Tangalos E. G., Cummings J. L., DeKosky S. T., Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001 56 9 1133 1142 2-s2.0-0035826925
58. Devanand D. P., Pelton G. H., Zamora D., Liu X., Tabert M. H., Goodkind M., Scarmeas N., Braun I., Stern Y., Mayeux R., Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. Archives of Neurology 2005 62 6 975 980 2-s2.0-20844445775 10.1001/archneur.62.6.975
59. Fridh M., Havelius U., Elofsson G., Hindfelt B., The pupillary response to tropicamide in Alzheimer's disease. Acta Ophthalmologica Scandinavica 1996 74 3 276 279 2-s2.0-0029957803
60. Kurz A., Marquard R., Fremke S., Leipert K. P., Pupil dilation response to tropicamide: a biological test for Alzheimer's disease? Pharmacopsychiatry 1997 30 1 12 15 2-s2.0-0031058204
61. Scinto L. F. M., Frosch M., Wu C. K., Daffner K. R., Gedi N., Geula C., Selective cell loss in Edinger-Westphal in asymptomatic elders and Alzheimer's patients. Neurobiology of Aging 2001 22 5 729 736 2-s2.0-0035160073 10.1016/S0197-4580(01)00235-4
62. Yasuno F., Tanimukai S., Sasaki M., Hidaka S., Ikejima C., Yamashita F., Kodama C., Mizukami K., Michikawa M., Asada T., Association between cognitive function and plasma lipids of the elderly after controlling for apolipoprotein E genotype. American Journal of Geriatric Psychiatry 2012 20 574 583 2-s2.0-79952520282 10.1097/JGP.0b013e318211819b
63. Elias P. K., Elias M. F., D'Agostino R. B., Sullivan L. M., Wolf P. A., Serum cholesterol and cognitive performance in the Framingham Heart Study. Psychosomatic Medicine 2005 67 1 24 30 2-s2.0-12744262955 10.1097/01.psy. 0000151745.67285.c2
64. Reitz C., Tang M.-X., Manly J., Schupf N., Mayeux R., Luchsinger J. A., Plasma lipid levels in the elderly are not associated with the risk of mild cognitive impairment. Dementia and Geriatric Cognitive Disorders 2008 25 3 232 237 2-s2.0-40549123954 10.1159/000115847
65. van Exel E., de Craen A. J. M., Gussekloo J., Houx P., Bootsma-Van Der Wiel A., Macfarlane P. W., Blauw G. J., Westendorp R. G. J., Association between high-density lipoprotein and cognitive impairment in the oldest old. Annals of Neurology 2002 51 6 716 721 2-s2.0-0036260959 10.1002/ana.10220
66. Gillum R. F., Obisesan T. O., High-density lipoprotein cholesterol, cognitive function and mortality in a U.S. national cohort. Lipids in Health and Disease 2011 10, article 26 2-s2.0-79251555951 10.1186/1476-511X-10-26
67. Lopez O. L., Jagust W. J., Dulberg C., Becker J. T., DeKosky S. T., Fitzpatrick A., Breitner J., Lyketsos C., Jones B., Kawas C., Carlson M., Kuller L. H., Risk factors for mild cognitive impairment in the cardiovascular health study cognition study. Archives of Neurology 2003 60 10 1394 1399 2-s2.0-0141889853 10.1001/archneur.60.10.1394
68. Tervo S., Kivipelto M., Hänninen T., Vanhanen M., Hallikainen M., Mannermaa A., Soininen H., Incidence and risk factors for mild cognitive impairment: a population-based three-year follow-up study of cognitively healthy elderly subjects. Dementia and Geriatric Cognitive Disorders 2004 17 3 196 203 2-s2.0-1542719830 10.1159/000076356
69. Farmer M. E., Kittner S. J., Abbott R. D., Wolz M. M., Wolf P. A., White L. R., Longitudinally measured blood pressure, antihypertensive medication use, and cognitive performance: The Framingham Study. Journal of Clinical Epidemiology 1990 43 5 475 480 2-s2.0-0025324432 10.1016/0895-4356(90)90136-D
70. Turana Y., Handayani Y. S., Relationship between vascular risk factors and physical exercise with cognitive function of the elderly in Jakarta. Proceedings of the INASH Scientific Meeting February 2010
71. Reitz C., Tang M.-X., Manly J., Mayeux R., Luchsinger J. A., Hypertension and the risk of mild cognitive impairment. Archives of Neurology 2007 64 12 1734 1740 2-s2.0-37149016808 10.1001/archneur.64.12.1734
72. Lautenschlager N. T., Flicker L., Vasikaran S., Leedman P., Almeida O. P., Subjective memory complaints with and without objective memory impairment: relationship with risk factors for dementia. American Journal of Geriatric Psychiatry 2005 13 8 731 734 2-s2.0-23944445542 10.1176/appi.ajgp.13.8.731